贝莱德于2026年9月29日通过取得股份保证权益的方式场外增持国药控股(01099)H股103.03万股。该笔为场外交易(代价性质:非现金资产),未经联交所公开市场撮合,不属二级市场直接买卖。
贝莱德此次增持前持有国药控股好仓1.21亿股,占比8.99%;增持后持股量为1.22亿股,好仓比例升至9.08%。
贝莱德于2026年9月29日通过取得股份保证权益的方式场外增持国药控股(01099)H股103.03万股。该笔为场外交易(代价性质:非现金资产),未经联交所公开市场撮合,不属二级市场直接买卖。
贝莱德此次增持前持有国药控股好仓1.21亿股,占比8.99%;增持后持股量为1.22亿股,好仓比例升至9.08%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.